CN110386965A - A kind of tembusu virus E protein B cell epitope and its encoding gene and application - Google Patents

A kind of tembusu virus E protein B cell epitope and its encoding gene and application Download PDF

Info

Publication number
CN110386965A
CN110386965A CN201810350513.3A CN201810350513A CN110386965A CN 110386965 A CN110386965 A CN 110386965A CN 201810350513 A CN201810350513 A CN 201810350513A CN 110386965 A CN110386965 A CN 110386965A
Authority
CN
China
Prior art keywords
tembusu virus
protein
cell epitope
virus
tembusu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810350513.3A
Other languages
Chinese (zh)
Other versions
CN110386965B (en
Inventor
赵冬敏
韩凯凯
黄欣梅
章丽娇
杨婧
刘宇卓
刘青涛
李银
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Academy of Agricultural Sciences
Original Assignee
Jiangsu Academy of Agricultural Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Academy of Agricultural Sciences filed Critical Jiangsu Academy of Agricultural Sciences
Priority to CN201810350513.3A priority Critical patent/CN110386965B/en
Publication of CN110386965A publication Critical patent/CN110386965A/en
Application granted granted Critical
Publication of CN110386965B publication Critical patent/CN110386965B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a kind of tembusu virus E protein B cell epitope and its encoding gene and applications.A kind of tembusu virus E protein B cell epitope, amino acid sequence is as shown in SEQ ID NO.1.Tembusu virus E protein B cell epitope of the present invention is preparing the application in tembusu virus vaccine.Duckling is immunized in the above-mentioned neoepitope Western of present invention Bacillus coli expression, can generate high-level specific antibody in duckling Immune inducing in vivo, which has neutralization to tembusu virus, and protects host from virus attack.B cell epitope has good antigenicity, is non-totivirus antigen, and safety is good, is free of unrelated foreign protein.In addition, also novel polyepitope vaccines can be constructed jointly with other kinds of epitope.Therefore, B cell epitope has good and wide application prospect.

Description

A kind of tembusu virus E protein B cell epitope and its encoding gene and application
Technical field
The invention belongs to molecular biology and immunological technique field, are related to a kind of tembusu virus E protein B cell epitope And its encoding gene and application.
Background technique
Since in April, 2010, the duck goose of the provinces and cities such as Fujian, Hebei, Zhejiang, Shandong, Jiangsu, Beijing has broken out one kind successively Sharply declined using appetite, egg production rapid drawdown is the new hair epidemic disease of main feature.Case dissect lesion is mainly seen in ovary, shows as Partially there is meningorrhagia in ovarian follicle bleeding, atrophy, denaturation and scarring, disease incidence almost 100%, death rate 5%- in group 28%, heavy economic losses is caused to duck goose aquaculture.Researcher passes through the laboratory diagnosis of pathogen separation and system, determines The disease is caused by the tembusu virus infection of flaviviridae, Flavivirus.Tembusu virus is year after year more in China since breaking out Pandemic is saved, and the host range infected is also constantly expanding, laying duck, kind duck, duckling, egg goose, kind goose and laying hen etc. are equal There is the Case report of tembusu virus infection, it has also become endanger one of the important epidemic disease of China's duck goose aquaculture.
Envelope protein (E protein) is the main structural proteins of tembusu virus, is merged in viruses adsorption, with host cell membrane And play a significant role during virus assembly.Meanwhile E protein is also the main antigenic component of flavivirus, containing there are many anti- Former epitope can generate protective immune response by inducing neutralizing antibody.
As a kind of new hair epidemic disease, the morbidity of tembusu virus disease is anxious, propagates rapidly, clinically more difficult to control.Tan Busu disease It can cause the cellular immunity and humoral immune response of body after poison infection, and E protein is then main protective antigens, containing more A epitope can generate protective immune response by inducing neutralizing antibody.Specific diagnosis, disease-resistant of the E protein in virus Play a significant role in cytotoxic drug design and vaccine research and development, therefore, the screening and identification of E protein epitope are to tembusu virus The prevention and control of disease are of great significance.
Summary of the invention
The purpose of the present invention is being directed to the above-mentioned deficiency of the prior art, a kind of tembusu virus E protein B cell table is provided Position and its encoding gene.
Another object of the present invention is to provide the applications of tembusu virus E protein B cell epitope.
The purpose of the present invention can be achieved through the following technical solutions:
A kind of tembusu virus E protein B cell epitope, amino acid sequence 301- TYPMCSNTFSLVKNPTDTGHGTVVVELSY-329(SEQ ID NO.1)。
Encode the gene of tembusu virus E protein B cell epitope of the present invention.
Its nucleotide sequence of the gene is as shown in SEQ ID NO.2.
Recombinant expression carrier containing tembusu virus E protein B cell epitope encoding gene of the present invention.
Bacillus coli cells containing tembusu virus E protein B cell epitope encoding gene of the present invention.
Tembusu virus E protein B cell epitope of the present invention is preparing the application in tembusu virus vaccine.
Tembusu virus E protein B cell epitope of the present invention is preparing the application in tembusu virus detection reagent.
Tembusu virus E protein B cell epitope encoding gene of the present invention is in preparing tembusu virus vaccine Using.
Tembusu virus E protein B cell epitope encoding gene of the present invention is preparing tembusu virus detection reagent In application.
The method for preparing B cell epitope of the present invention is obtained by artificial directly synthesis or by vivoexpression.Such as By the microbial expression peptide of the recombinant nucleic acid molecules containing the peptide needed for the coding under transcripting promoter appropriate control, and From peptide needed for affiliated microorganism-collecting.
The utility model has the advantages that
One new tembusu virus E protein B cell epitope of first identified of the present invention, amino acid sequence 301- TYPMCSNTFSLVKNPTDTGHGTVVVELSY-329.Based on the discovery, the B cell epitope of present invention Bacillus coli expression Immune duckling, inducing producing specificity antibody neutralize tembusu virus, so that duckling be protected to attack from tembusu virus.Knot Fruit discovery, sequence are that the B cell epitope of 301-TYPMCSNTFSLVKNPTDTGHGTVVVELSY-329 can be in duckling Immune inducing in vivo High-level specific antibody is generated, there is neutralization to tembusu virus, reduction attacks viral level in malicious duckling body, exempts from it By viral damage.
B cell epitope provided by the invention, neutralizes virus by induced high levels specific antibody, protect host from Virus attack.B cell epitope has good antigenicity, is non-totivirus antigen, and safety is good, is free of unrelated foreign protein.This Outside, also novel polyepitope vaccines can be constructed jointly with other kinds of epitope.Therefore, B cell epitope has good and wide Application prospect.
Detailed description of the invention
The SDS-PAGE identification of Fig. 1 tembusu virus E protein B cell epitope purifying
Neutralization of the anti-tembusu virus E protein B cell epitope serum of Fig. 2 to virus
Specific embodiment
The acquisition of embodiment 1B cell epitope
According to the coding gene sequence of tembusu virus E protein B cell epitope, coding base is obtained using artificial synthesis Because of segment, it is inserted into plasmid pGEX-4t-1 by EcoR I and Sal I restriction enzyme site and obtains recombinant plasmid pGEX-4t-B.It will Expression vector pGEX-4t-B is imported in Escherichia coli, obtains the engineered strain of expression tembusu virus E protein B cell epitope.It will Obtained engineered strain inoculation LB culture medium, to OD600nmFor the IPTG of final concentration of 1mmol/L is added when 0.4-0.6 to containing The engineering bacteria of expression vector pGEX-4t-B carries out the inducing expression of albumen.Expression product uses Glutathione-agarose (Sigma) it is purified, operating procedure carries out to specifications.The tembusu virus E protein B cell epitope purified carries out SDS-PAGE identification, obtains purpose antigen (Fig. 1) as the result is shown.
2 tembusu virus E protein B cell epitope inducing producing specificity antibody of embodiment
1, the 9 age in days duckling of B cell epitopic immune for obtaining embodiment 1, every 200 μ g, first immunisation are used in equal volume not The emulsification of family name's Freund's complete adjuvant.Progress booster immunization is primary after 2 weeks immune, every 200 μ g, and booster immunization is incomplete with isometric Freund Adjuvant adjuvant emulsion.The PBS of same volume is immunized in control group duckling, remaining processing is identical.
2,2 weeks after booster immunization, wing venous blood sampling is carried out to immune group and control group duckling, serum is separated, by indirect ELISA detects specific antibody titres.
Result of implementation: B cell epitope-specific antibodies potency is above 1:3200 in immune group duckling serum, and control group B cell epitope-specific antibodies potency is feminine gender in duckling serum, and it is good to illustrate that tembusu virus E protein B cell epitope has Good immunogenicity can induce duckling and generate high-level specific antibody.
Neutralization of the 3 tembusu virus E protein B cell epitope-specific antibodies of embodiment to virus
1, BHK-21 cell is paved with 24 porocyte culture plates by normal cell cultural method.
2, the serum for obtaining embodiment 2,56 DEG C of inactivation 30min, with the RPMI1640 dilution 10 containing 1% fetal calf serum Times.Serum after dilution is subjected to 2 times of gradient dilutions, after taking 100 μ l dilute serum and 100 μ l tembusu virus to mix, 37 DEG C of incubation 2h.Control group is that virus is incubated for the RPMI1640 containing 1% fetal calf serum.
3, above-mentioned mixtures incubated is added on the BHK-21 cell for having grown up to single layer, removes culture after 4 DEG C of placement 1h Supernatant.PBS washed once, and rejoin the RPMI1640 containing 1% fetal calf serum, 37 DEG C of incubation 2h.PBS washed once, and receive Collect cell, fluorescence quantitative RT-RCR detects viral nucleic acid content, using relative quantitation method (2-ΔΔCt) analyzed.Detection disease Primer used in malicious nucleic acid are as follows: upstream primer: 5 '-GTGAGATCTTACTGCTATGAG-3 '；Downstream primer: 5 '- ACTTGGCACATGTCTGTATGC-3'.Internal reference selects GAPDH gene, upstream primer: 5 '-ACTTGGCACATGTCTGTATGC- 3'；Downstream primer: 5 '-CACCAGCATCACCCCATTT-3 '.
Result of implementation: immune group duckling serum has neutralization to tembusu virus, and the maximum with neutralization activity is dilute Releasing multiple is 1:80, and control group duckling serum does not have neutralization (Fig. 2) to tembusu virus.
The protest test of duckling is immunized in embodiment 4
1, the duckling behind in embodiment 2 booster immunization 2 weeks is subjected to tembusu virus challenge test.Every is attacked toxic dose It is 104TCID50。
2, it attacks after poison 1-5 days, daily aseptic collection duckling wing venous blood, separates serum, inoculation has grown up to the BHK- of single layer 21 cells.After 37 DEG C of incubation 2h, PBS is washed 3 times, and the RPMI1640 for containing 1% fetal calf serum is added, and 37 DEG C are cultivated 3 days.It collects thin Born of the same parents, fluorescence quantitative RT-RCR detect viral nucleic acid content.Viral nucleic acid test positive is considered as virus infection, calculates protection Index (PI),
Result of implementation: tembusu virus nucleic acid is not detected in immune group duckling wing venous serum, negative control group detects Tembusu virus nucleic acid, therefore the protective index PI=100% of B cell neoepitope Western, illustrate immune tembusu virus E protein B cell neoepitope Western provides complete protection to tembusu virus infection.
Sequence table
<110>Jiangsu Province Agriculture Science Institute
<120>a kind of tembusu virus E protein B cell epitope and its encoding gene and application
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 29
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 1
Thr Tyr Pro Met Cys Ser Asn Thr Phe Ser Leu Val Lys Asn Pro Thr
1 5 10 15
Asp Thr Gly His Gly Thr Val Val Val Glu Leu Ser Tyr
20 25
<210> 2
<211> 87
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
acctacccga tgtgtagcaa tacattttcc ctagtgaaga atcctaccga cactgggcat 60
ggcactgtcg tggtggaatt gtcttat 87

Claims (9)

1. a kind of tembusu virus E protein B cell epitope, amino acid sequence is as shown in SEQ ID NO.1.
2. encoding the gene of tembusu virus E protein B cell epitope described in claim 1.
3. gene according to claim 2, it is characterised in that its nucleotide sequence of the gene such as SEQ ID NO.2 institute Show.
4. containing the recombinant expression carrier of gene described in claim 2 or 3.
5. containing the Bacillus coli cells of gene described in claim 2 or 3.
6. tembusu virus E protein B cell epitope described in claim 1 is preparing the application in tembusu virus vaccine.
7. tembusu virus E protein B cell epitope described in claim 1 is preparing answering in tembusu virus detection reagent With.
8. gene described in claim 2 or 3 is preparing the application in tembusu virus vaccine.
9. gene described in claim 2 or 3 is preparing the application in tembusu virus detection reagent.
CN201810350513.3A 2018-04-18 2018-04-18 Tembusu virus E protein B cell epitope and coding gene and application thereof Active CN110386965B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810350513.3A CN110386965B (en) 2018-04-18 2018-04-18 Tembusu virus E protein B cell epitope and coding gene and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810350513.3A CN110386965B (en) 2018-04-18 2018-04-18 Tembusu virus E protein B cell epitope and coding gene and application thereof

Publications (2)

Publication Number Publication Date
CN110386965A true CN110386965A (en) 2019-10-29
CN110386965B CN110386965B (en) 2022-09-27

Family

ID=68284044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810350513.3A Active CN110386965B (en) 2018-04-18 2018-04-18 Tembusu virus E protein B cell epitope and coding gene and application thereof

Country Status (1)

Country Link
CN (1) CN110386965B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628831A (en) * 2015-03-20 2015-05-20 浙江省农业科学院 Duck tembusu virus (DTMUV) protein E linear B cell antigenic epitope polypeptide and application thereof
CN107656066A (en) * 2017-09-07 2018-02-02 华中农业大学 A kind of duck tembusu virus E protein truncated protein and application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628831A (en) * 2015-03-20 2015-05-20 浙江省农业科学院 Duck tembusu virus (DTMUV) protein E linear B cell antigenic epitope polypeptide and application thereof
CN107656066A (en) * 2017-09-07 2018-02-02 华中农业大学 A kind of duck tembusu virus E protein truncated protein and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
韩凯凯等: "鹅新型坦布苏病毒囊膜蛋白的二级结构与B细胞表位预测", 《江苏农业科学》, vol. 42, no. 6, 31 December 2014 (2014-12-31) *

Also Published As

Publication number Publication date
CN110386965B (en) 2022-09-27

Similar Documents

Publication Publication Date Title
CN111018995A (en) B, T cell epitope tandem fusion vaccine for African swine fever
Ivanov et al. Vaccination with viral protein-mimicking peptides postpones mortality in domestic pigs infected by African swine fever virus
CN105198970A (en) VP (viral protein)0 recombinant protein of DHAV (duck hepatitis A virus)-1 as well as preparation method and application of VP0 recombinant protein
CN101879312B (en) Broad spectrum type influenza vaccine and preparation method thereof
CN102816246A (en) Human cytomegalo virus immunogen fusion protein as well as preparation method and usage thereof
CN104974249A (en) Riemerella anatipestifer OmpA/MotB truncated recombinant protein, antibody and preparation method and application thereof
CN102210860A (en) Mycobacterium tuberculosis TB10.4-F1 fusion protein vaccine and preparation method thereof
CN104548087B (en) Epitope vaccine for resisting A/B subgroup avian leucosis virus infection and preparation method and application of epitope vaccine
CN110845584B (en) Swine fever virus envelope protein oligomeric protein body and preparation method and application thereof
CN102127554A (en) Japanese encephalitis particle vaccine and preparation method and application thereof
CN112812193A (en) Recombinant protein vaccine of norovirus GII.4 type and enterovirus 71 type
CN105085672B (en) 3D protein specific monoclonal immunoglobulin A antibodies and compositions thereof
CN104479028B (en) Bovine rota VP8* subunits recombinate chimeric protein and its application
CN107557347A (en) New virus sample particle, its preparation method and the application of enterovirns type 71
CN110386965A (en) A kind of tembusu virus E protein B cell epitope and its encoding gene and application
CN113248575B (en) Recombinant protein vaccine for SARS-CoV-2 and its preparing method
CN108624611A (en) The preparation and its application of infectious bursa of Fabricius virus virus-like particle
Zhang et al. Efficient capture and detection of Zika virion by polyclonal antibody against prokaryotic recombinant envelope protein
CN112724205B (en) Method for preparing virus-like particles from C hepatitis E virus 239 protein and application thereof
KR102451412B1 (en) Novel immunopotent recombinant protein with simultaneous induction of cellular and humoral immune responses and broad spectrum of protective efficacy, and foot-and-mouth disease (FMD) vaccine composition comprising the same
CN108676078B (en) Use of antigens causing the antibody-dependent potentiation of tembusu virus
IL312520A (en) Modification of engineered influenza hemagglutinin polypeptides
CN113827714A (en) H7N9 subtype avian influenza virus-like particle vaccine preparation and application thereof
CN103554233B (en) Duck plague virus (DPV) UL13 intercepted recombinant protein and polyclonal antibody, preparation method and application thereof
CN103435690B (en) DNA vaccination of a kind of hepatitis C virus and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant